Results 211 to 220 of about 70,416 (256)

Multi-Target Tyrosine Kinase Inhibitors as Adjuvant Therapy for Hepatocellular Carcinoma Patients Who Achieve Complete Response After Transarterial Chemoembolization: A Real-World Study. [PDF]

J Hepatocell Carcinoma
Tang W, Huang Y, Wang T, Yang J, Zhao Z.
europepmc   +1 more source

The Survival Advantage of Prior Curative Hepatectomy in Patients with Hepatocellular Carcinoma Receiving First-Line Multikinase Inhibitors: A Propensity Score-Adjusted Study. [PDF]

J Hepatocell Carcinoma
Wu JM, Li GH, Lee CC, Chen JY, Yang SF, Hsueh KC.   +5 more
europepmc   +1 more source

Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis. [PDF]

Front Immunol
Su Y, Cai T, Wei J, Huang Q, Yao C, Fu L, Zheng J, Guo H, Gui X.   +8 more
europepmc   +1 more source

Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma. [PDF]

Gut
Pan Y, Zhang X, Wong CC, Chen H, Ma S, Lee TK, Yuan K, Liang C, Zhou X, Lau HCH, Huang P, Chen D, Wang L, Ding Y, Wei Q, Cheung AHK, To KF, Yu J.   +17 more
europepmc   +1 more source

AFP Stimulates Glucose Metabolic Reprogramming Contributing to Hepatocellular Carcinoma Resist Sorafenib Through Activating PI3K/AKT Signalling Pathway. [PDF]

J Cell Mol Med
Zhou Y, Feng S, Chen Y, Lin B, Li W, Dong X, Liu K, Yin Q, Li M, Zhu M.   +9 more
europepmc   +1 more source

Efficacy of immune-based combinations across treatment lines in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. [PDF]

Front Pharmacol
Zhao W, Wu Z, Qiao S, Kou Q, Liu Z, Zhang X.   +5 more
europepmc   +1 more source

Pretreatment Prognostic Nutritional Index Predicts Progression-Free Survival in BCLC Stage C Hepatocellular Carcinoma Treated with Sorafenib. [PDF]

Cancer Manag Res
Aydın U, Dikilitaş M, Balıkçı Çiçek İ, Pamuk ÖA, Sadak Öcal Z, Danacı Y, Alizade E.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sorafenib

Reactions Weekly, 2019
Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Sorafenib inhibited tumor growth and angiogenesis through targeting both the RAF/MEK/ERK pathway and receptor tyrosine kinases.
Ahmed A, Abdelgalil, Hamad M, Alkahtani, Fahad I, Al-Jenoobi   +2 more
  +5 more sources

Sorafenib

Expert Opinion on Pharmacotherapy, 2006
Sorafenib is a small molecule inhibitor of several kinases involved in tumour proliferation and tumour angiogenesis including Raf, VEGFR and platelet derived growth factor receptor. In vivo Raf kinase inhibition has been observed in pharmacodynamic studies. Sorafenib is one of several VEGF-targeting compounds with recently demonstrated substantial anti-
Olwen, Hahn, Walter, Stadler
openaire   +4 more sources

Sorafenib

Reactions Weekly, 2009
Sorafenib (BAY 43-9006, Nexavar) is a novel oral kinase inhibitor that targets multiple tyrosine kinases in vivo and in vitro. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the raf-ras pathway, vascular endothelial growth factor (VEGF) pathway, and FMS-like tyrosine kinase 3 (FLT3).
  +7 more sources